Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma
- PMID: 33787836
- PMCID: PMC8014201
- DOI: 10.1001/jamadermatol.2021.0023
Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma
Abstract
Importance: Early-stage melanoma, among the most common cancers in the US, is typically treated with wide local excision. However, recent advances in immunohistochemistry have led to an increasing number of these cases being excised via Mohs micrographic surgery (MMS). Although studies of resections for other cancers have reported that facility-level factors are associated with patient outcomes, it is not yet established how these factors may affect outcomes for patients treated with Mohs micrographic surgery.
Objective: To evaluate the association of treatment center academic affiliation and case volume with long-term patient survival after MMS for T1a-T2a invasive melanoma.
Design, setting, and participants: In a retrospective cohort study, 4062 adults with nonmetastatic, T1a-T2a melanoma diagnosed from 2004 to 2014 and treated with MMS in the National Cancer Database (NCDB) were identified. The NCDB includes all reportable cases from Commission on Cancer-accredited facilities and is estimated to capture approximately 50% of all incident melanomas in the US. Multivariable survival analyses were conducted using Cox proportional hazards models. Data analysis was conducted from February 27 to August 18, 2020.
Exposures: Treatment facility characteristics.
Main outcomes and measures: Overall survival.
Results: The study population included 4062 patients (2213 [54.5%] men; median [SD] age, 60 [16.3] years) treated at 462 centers. Sixty-two centers were top decile-volume facilities (TDVFs), which treated 1757 patients (61.9%). Most TDVFs were academic institutions (37 of 62 [59.7%]). On multivariable analysis, treatment at an academic center was associated with a nearly 30% reduction in hazard of death (hazard ratio, 0.730; 95% CI, 0.596-0.895). In a separate analysis, treatment at TDVFs was also associated with improved survival (hazard ratio, 0.795; 95% CI, 0.648-0.977).
Conclusions and relevance: In this cohort study, treatment of patients with T1a-T2a invasive melanoma excised with MMS at academic and top decile-volume (≥8 cases per year) facilities was associated with improved long-term survival compared with those excised by MMS at nonacademic and low-volume facilities. Identification and protocolization of the practices of these facilities may help to reduce survival differences between centers.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8014201/bin/jamadermatol-e210023-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8014201/bin/jamadermatol-e210023-g002.gif)
Comment in
-
Mohs Micrographic Surgery for Melanoma-Do Outcomes Vary Among Treatment Facilities?JAMA Dermatol. 2021 May 1;157(5):513-515. doi: 10.1001/jamadermatol.2021.0022. JAMA Dermatol. 2021. PMID: 33787822 No abstract available.
Similar articles
-
Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma.JAMA Dermatol. 2019 Nov 1;155(11):1252-1259. doi: 10.1001/jamadermatol.2019.2890. JAMA Dermatol. 2019. PMID: 31553403 Free PMC article.
-
Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities.JAMA Dermatol. 2021 Jan 1;157(1):84-89. doi: 10.1001/jamadermatol.2020.3950. JAMA Dermatol. 2021. PMID: 33084853 Free PMC article.
-
National utilization patterns of Mohs micrographic surgery for invasive melanoma and melanoma in situ.J Am Acad Dermatol. 2015 Jun;72(6):1060-5. doi: 10.1016/j.jaad.2015.02.1122. Epub 2015 Mar 29. J Am Acad Dermatol. 2015. PMID: 25824274
-
Mohs micrographic surgery for the treatment of malignant melanoma.Clin Dermatol. 2009 Nov-Dec;27(6):597-602. doi: 10.1016/j.clindermatol.2008.09.018. Clin Dermatol. 2009. PMID: 19880047 Review.
-
Mohs micrographic surgery for the treatment of melanoma.Dermatol Clin. 2012 Jul;30(3):503-15. doi: 10.1016/j.det.2012.04.010. Epub 2012 Jun 5. Dermatol Clin. 2012. PMID: 22800554 Review.
Cited by
-
High-volume facilities are significantly more likely to use guideline-adherent systemic immunotherapy for metastatic Merkel cell carcinoma: implications for cancer care regionalization.Arch Dermatol Res. 2024 Feb 13;316(3):86. doi: 10.1007/s00403-024-02817-4. Arch Dermatol Res. 2024. PMID: 38349538
-
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis.Ann Hematol. 2023 Jun;102(6):1443-1458. doi: 10.1007/s00277-023-05194-6. Epub 2023 Apr 24. Ann Hematol. 2023. PMID: 37093241
References
-
- American Cancer Society . Cancer Facts & Figures 2021. American Cancer Society; 2021.
-
- National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines): melanoma, version 1.2020). Accessed February 11, 2020. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical